CERo Therapeutics (CERO) Holdings announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office, and one European patent application has ...

This, in a nutshell, is what happened to the Patent Office. In 1952, it was simple. Then, over the years, things got more complicated, and yet for decades it was OK.

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue ...

European DataWarehouse (EDW), Europe’s first securitisation repository, today announced the opening of a new office in Bangalore, India.

REHOVOT, Israel - CollPlant Biotechnologies (NASDAQ:CLGN), a biotechnology company with a current market capitalization of $29 million, has been granted a new patent by the European Patent and ...

Merck gets lift from U.S. patent office in battle over injectable form of Keytruda Dispute with Halozyme Therapeutics could affect plans to extend its franchise product Manage alerts for this article ...

Anon June 5, 2025 10:14 am. The concluding remarks can be (should be?) bolstered with reference to 37 CFR 1.2 (my emphasis added): 1.2 Business to be transacted in writing.

Delhi HC seeks Centre’s reply on plea alleging unlawful data access in Patent Office Plea by patent officers’ body seeks an investigation into how a multinational company gained unauthorised ...

The Delhi High Court has upheld a decision of the Patent Office rejecting a divisional application from Japanese drug maker Zeria Pharmaceuticals, related to a drug for the treatment of certain ...

The U.S. Patent and Trademark Office (USPTO) held a “USPTO Hour” Wednesday in which it announced the results of a study it apparently conducted over the last five years into “Applications ...